The trajectory of companies tied to the drug's history presents a complex investment picture . While the initial boom generated substantial gains, generic competition have significantly eroded revenue. Investing in connected pharmaceutical companies now requires a thorough assessment of intellectual property protection , evolving patient changes… Read More